PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Eberherr, A.C. ; Maaske, A. ; Wolf, C. ; Giesert, F. ; Berutti, R. ; Rusha, E. ; Pertek, A. ; Kastlmeier, M.T. ; Voss, C. ; Plummer, M. ; Sayed, A. ; Graf, E. ; Effner, R. ; Volz, T.* ; Drukker, M. ; Strom, T.M. ; Meitinger, T. ; Stöger, T. ; Buyx, A.M.* ; Hagl, B. ; Renner, E.D.

Rescue of STAT3 function in hyper-IgE syndrome using adenine base editing.

CRISPR J. 4, 178-190 (2021)
DOI PMC
Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
STAT3-hyper IgE syndrome (STAT3-HIES) is a primary immunodeficiency presenting with destructive lung disease along with other symptoms. CRISPR-Cas9-mediated adenine base editors (ABEs) have the potential to correct one of the most common STAT3-HIES causing heterozygous STAT3 mutations (c.1144C>T/p.R382W). As a proof-of-concept, we successfully applied ABEs to correct STAT3 p.R382W in patient fibroblasts and induced pluripotent stem cells (iPSCs). Treated primary STAT3-HIES patient fibroblasts showed a correction efficiency of 29% ± 7% without detectable off-target effects evaluated through whole-genome and high-throughput sequencing. Compared with untreated patient fibroblasts, corrected single-cell clones showed functional rescue of STAT3 signaling with significantly increased STAT3 DNA-binding activity and target gene expression of CCL2 and SOCS3. Patient-derived iPSCs were corrected with an efficiency of 30% ± 6% and differentiated to alveolar organoids showing preserved plasticity in treated cells. In conclusion, our results are supportive for ABE-based gene correction as a potential causative treatment of STAT3-HIES.
Impact Factor
Scopus SNIP
Scopus
Cited By
Altmetric
6.071
0.000
6
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Sprache englisch
Veröffentlichungsjahr 2021
HGF-Berichtsjahr 2021
ISSN (print) / ISBN 2573-1599
e-ISSN 2573-1602
Zeitschrift The CRISPR Journal
Quellenangaben Band: 4, Heft: 2, Seiten: 178-190 Artikelnummer: , Supplement: ,
Verlag Mary Ann Liebert
Verlagsort 140 Huguenot Street, 3rd Fl, New Rochelle, Ny 10801 Usa
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Environmental Medicine (IEM)
Institute of Developmental Genetics (IDG)
Institute of Neurogenomics (ING)
Institute of Lung Health and Immunity (LHI)
Institute of Human Genetics (IHG)
Institute of Stem Cell Research (ISF)
POF Topic(s) 30202 - Environmental Health
30204 - Cell Programming and Repair
30205 - Bioengineering and Digital Health
30501 - Systemic Analysis of Genetic and Environmental Factors that Impact Health
30504 - Mechanisms of Genetic and Environmental Influences on Health and Disease
Forschungsfeld(er) Allergy

Genetics and Epidemiology
Lung Research
Stem Cell and Neuroscience
PSP-Element(e) G-503400-002
G-508200-029
G-503400-003
G-500500-001
G-503292-001
G-505000-001
G-500700-001
G-503400-001
G-500800-001
G-552400-001
Förderungen Helmholtz Translational Clinical Project
Helmholtz-Future topic "Immunology and Inflammation''
German Research Foundation
Fritz Bender Stiftung
DOI 10.1089/crispr.2020.0111
WOS ID WOS:000642276500006
Scopus ID 85104807802
PubMed ID 33876960
Erfassungsdatum 2021-06-08
[➜Korrektur melden]